Compare Crispr Therapeutics AG (CRSP) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Wendys Co — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while Wendys Co trades at $8.55 (market cap $1.44B). The key difference: Crispr Therapeutics AG is far larger — about 3.6× Wendys Co's market cap, and Wendys Co pays a 3.71% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WEN | |
|---|---|---|
Market Cap | $5.23B | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $10.68 |
52-Week Low | $44.34 | $6.17 |
Enterprise Value | $3.65B | $5.17B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Wendy's (WEN) stock is trading at $8.57, up 17.4% in 24 hours, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 EPS of $0.18, beating expectations, but faces challenges including a 50% dividend cut, withdrawn 2026 outlook, and declining U.S. same-store sales as Burger King overtakes it as the second-largest U.S. burger chain. Financial metrics show a P/E of 11.44 and ROE of 108.04%, but net income margin has fallen to 5.72% for 2026.
The outlook is cautious; while valuation appears reasonable and recent earnings beats are positive, significant operational headwinds, high debt, and intense competition pose risks. Analyst sentiment is mixed with a majority Hold rating, reflecting uncertainty around the new CEO's turnaround plan. Investment opportunity hinges on successful execution of strategic initiatives to restore growth and profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
